Moreover, the observed anti-ferroptosis function of LAPTM4B and the potential clinical significance were further supported by the data in animal experiments, in NSCLC patients’ samples, as well as in the cancer databases, underscoring that the anti-ferroptosis role of LAPTM4B might promote NSCLC progression and diminish patients’ survival probability. Here, LAPTM4B is linked to non-small cell lung carcinoma.